Site of effect of LY2951742 for migraine prophylaxis--authors' reply

Affiliations

¹ Department of Neurology, Mayo Clinic, Phoenix, AZ, USA. Electronic address: dodick.david@mayo.edu.
² NIHR Wellcome Trust Clinical Research Facility, King's College London, London, UK.
³ Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁴ Eli Lilly and Company, Indianapolis, IN, USA.
⁵ Arteaus Therapeutics, Cambridge, MA, USA.

Comment

David W Dodick et al. Lancet Neurol. 2015 Jan.

. 2015 Jan;14(1):32-3.

doi: 10.1016/S1474-4422(14)70309-6.

¹ Department of Neurology, Mayo Clinic, Phoenix, AZ, USA. Electronic address: dodick.david@mayo.edu.
² NIHR Wellcome Trust Clinical Research Facility, King's College London, London, UK.
³ Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁴ Eli Lilly and Company, Indianapolis, IN, USA.
⁵ Arteaus Therapeutics, Cambridge, MA, USA.

No abstract available

Comment on

Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.
Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS. Dodick DW, et al. Lancet Neurol. 2014 Sep;13(9):885-92. doi: 10.1016/S1474-4422(14)70128-0. Epub 2014 Aug 10. Lancet Neurol. 2014. PMID: 25127173 Clinical Trial.
Site of effect of LY2951742 for migraine prophylaxis.
Tfelt-Hansen P. Tfelt-Hansen P. Lancet Neurol. 2015 Jan;14(1):31-2. doi: 10.1016/S1474-4422(14)70306-0. Lancet Neurol. 2015. PMID: 25496894 No abstract available.